Skip to content
Government TAS, Medical Health Aged Care

Nation-leading partnered prescribing pilot to support Tasmanian aged care residents

Pharmaceutical Society of Australia (PSA) 2 mins read

Joining pharmacists on R U OK? Day, Tasmanian Health Minister Guy Barnett MP announced that Tasmanian pharmacists will soon be able to prescribe medicines for aged care patients under a new pilot program following the release of recommendations from the Review of Tasmanian Pharmacists’ Scope of Practice, which have been accepted by the state government in full.

The Tasmanian Health Minister also announced that patients will soon be able to access treatment for urinary tract infections (UTIs).

Pharmaceutical Society of Australia (PSA) Tasmanian President David Peachey MPS said the move demonstrated a commitment to improving accessible care for Tasmanians.

“I am proud to see the Tasmanian Government leading the nation on reform to best support aged care patients and our broader health system,” Mr Peachey said.

“It’s clear that we need to do more for our older Australians living in residential aged care. Allowing pharmacists to write repeat prescriptions or change the dose of an existing drug will free up hundreds of GP hours for complex and emerging needs.

“Pharmacists in many parts of Australia are already initiating treatment for uncomplicated UTIs, supporting safe, timely access to care for thousands of patients,” Mr Peachey said.

“Today’s announcement brings Tasmania in line with programs around the country.

“Pharmacists have shown that we can and should be doing more to improve patients’ access to care and strengthen the health system.”

Mr Peachey has also reaffirmed PSA’s support for expanding pharmacist scope of practice to better support Tasmanians. 

“The recommendations from the Scope of Practice review are a positive step toward a health system that works for patients.

“Recommendations from the review will make care more accessible for many Tasmanians, from structured prescribing to medication charting.

"This is recognition that pharmacists can and should do more as our most accessible health care professionals. This is particularly important as we mark R U OK? Day and the role that pharmacists can play in supporting patient's mental health. 

“PSA is committed to working collaboratively with the Health Minister and the Tasmanian Government to progress all recommendations as soon as possible.”

 

Media contact:   Georgia Clarke   M: 0480 099 798      E: georgia.clarke@psa.org.au

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

Follow us on socials:      Facebook     Twitter      LinkedIn     Instagram

More from this category

  • Medical Health Aged Care
  • 29/05/2024
  • 17:07
JJP Biologics

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist,…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:54
NDARC

Long-term prescription opioid use after hospital declining: study

UNSW Sydney medical researchers have shed light on post-hospital prescription opioid use. A large, linked data study has detailed the scale of prescription opioid…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:45
Cleo Diagnostics Limited ASX.COV

Cleo’s Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark

Highlights A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers” The study confirmed that CLEO’s initial test for the surgical triage market:– Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;– Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; and– Can be easily adopted for use into clinical practice. The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention. MELBOURNE, AUSTRALIA, 29…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.